Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- US Merck Initiates Multinational PII/III Study for BACE Inhibitor for Alzheimer’s Disease
December 5, 2012
- Pediatric NDA for AcipHex Granted Priority Review by US FDA: Eisai
December 4, 2012
- Hospira Applies for Irinotecan Generic for Pediatric Malignant Solid Tumors Based on Data from the Public Domain
December 4, 2012
- Novartis Concludes Comarketing Agreement with Taisho for SGLT-2 Inhibitor Luseogliflozin
December 4, 2012
- Sanwa Kagaku, Kowa Launch DPP-4 Inhibitor Suiny on November 30
December 3, 2012
- Novartis AG Receives First Approval for Cell-Culture Influenza Vaccine in the US
December 3, 2012
- Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
- US FDA Accepts NDA Filing for Tivozanib: Astellas
November 30, 2012
- CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
- China’s Drug Costs to Expand to 11 Trillion Yen in 2030 by 5% Annual Growth: UtoBrain
November 29, 2012
- Long-Listed Products to Be Switched to Combination Drugs, Original Drugs Rather than Generics: President Sawai
November 29, 2012
- Sawai to Seek Alternative Suppliers for All of Its Products
November 29, 2012
- Santen Files Anti-Allergic Ophthalmic Solution DE-114
November 29, 2012
- Chugai, Nippon Shinyaku Conclude Codevelopment, Comarketing Agreement for Anti-CD20 Antibody
November 29, 2012
- Takeda to Establish Medical Affairs Department within Development Division
November 28, 2012
- Approximately 30% of Doctors Conduct ALK Gene Test in All Patients: Pfizer Survey
November 28, 2012
- Pfizer Launches Glycylcycline Antibiotic Tygacil
November 27, 2012
- 8 Companies’ Entries to COPD Market Turn It into Red Ocean
November 27, 2012
- Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
- Health Professionals Voice Concerns over JPMA Transparency Guidelines
November 26, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…